

RESEARCH

Open Access



# The usefulness of tranexamic acid for bleeding symptoms of chronic consumptive coagulopathy complicated by aortic disease: a single-institute, retrospective study of 14 patients

Naruko Suzuki<sup>1</sup>, Nobuaki Suzuki<sup>2\*</sup>, Yuka Kawaguchi<sup>1</sup>, Shuichi Okamoto<sup>3</sup>, Takeshi Kanematsu<sup>3</sup>, Akira Katsumi<sup>4</sup>, Atsuo Suzuki<sup>5</sup>, Shogo Tamura<sup>6,7</sup>, Tetsuhito Kojima<sup>8</sup>, Hitoshi Kiyoi<sup>1</sup> and Tadashi Matsushita<sup>2</sup>

## Abstract

**Background** Tranexamic acid (TXA) is an antifibrinolytic drug that blocks lysine-binding sites on the profibrinolytic enzyme plasminogen. Aortic diseases with chronic consumption coagulopathy may lead to disseminated intravascular coagulation (DIC) and cause fatal bleeding. Although the use of antifibrinolytic agents in DIC is generally not recommended due to enhanced fibrin deposition risking thrombotic symptoms, the efficacy of TXA has been reported in several cases of DIC with aortic diseases. However, the efficacy and safety of TXA for bleeding symptoms of chronic consumption coagulopathy with aortic diseases have not been studied in detail.

**Methods** We evaluated the efficacy of TXA in 14 patients with chronic consumptive coagulopathy due to aortic disease complicated by bleeding symptoms. Changes in coagulation and fibrinolysis parameters from baseline were analyzed with Wilcoxon matched-pairs signed-rank tests, excluding missing values. Kaplan-Meier curves were used to analyze overall survival.

**Results** Median age was 78.5 years (range, 66–89 years) and median observation period was 448 days (range, 0–2282 days). Twelve patients had chronic renal failure and 1 patient had chronic liver failure. Before starting treatment, median Japanese Ministry of Health and Welfare DIC diagnostic criteria score was 8 (range, 4–11) and median platelet count was  $64 \times 10^9/L$  (range,  $25\text{--}97 \times 10^9/L$ ). Twelve patients underwent evaluation of bleeding symptoms after introduction of TXA, and 10 of those 12 patients showed improved bleeding tendencies within 30 days (median, 5.0 days). One patient with chronic liver failure showed worsening of bleeding symptoms. Although only one patient was initiated TXA in combination with anticoagulants, no significant worsening of thrombotic events was observed within 30 days.

**Conclusions** TXA therapy appears effective against chronic consumptive coagulopathy with bleeding due to aortic disease, with few side effects.

\*Correspondence:

Nobuaki Suzuki

suzukin@med.nagoya-u.ac.jp

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

**Keywords** Disseminated intravascular coagulation, Tranexamic acid, Aortic aneurysm, Aneurysm, Dissecting, Endovascular procedures

## Background

As Japan has a rapidly aging population and the numbers of patients with aortic disease are increasing year by year, the treatment demand for frail patients with aortic disease is expected to increase [1]. Aortic diseases such as aortic aneurysms and aortic dissection are known to be complicated by consumptive coagulopathy. Some cases lead to the hyperfibrinolytic form of disseminated intravascular coagulation (DIC), a condition in which various underlying diseases activate the coagulation system. Zhang et al. reported that the clinical courses in 22.1% of patients with aortic aneurysm were complicated by chronic consumptive coagulopathy, and 4% progressed to DIC, which can result in fatal bleeding complications [2, 3].

The optimal method for treating chronic consumptive coagulopathy is treatment of the primary disease [3]. However, in cases where the primary disease is difficult to control, anticoagulants and antifibrinolytics may be used to improve the symptoms of chronic consumptive coagulopathy-related thrombosis and bleeding [2].

Tranexamic acid (TXA) is an antifibrinolytic drug that blocks lysine-binding sites on plasminogen molecules. TXA shows hemostatic effects in conditions with bleeding tendencies [4]. As a result, this agent is used in certain conditions with abnormal bleeding or bleeding tendencies in which local or systemic hyperfibrinolysis is considered to be involved [5]. Prolonged TXA administration has been successfully used to treat bleeding in several cases of chronic DIC associated with aortic disease (CDAAD) [6–11]. However, no studies appear to have examined TXA for bleeding symptoms of chronic consumption coagulopathy with aortic diseases. We

report a single-center, retrospective study of 14 cases in which TXA was used to treat consumption coagulopathy due to aortic disease complicated by bleeding symptoms.


## Methods

### Eligible patients

Patients with underlying aortic disease and a history of TXA administration at our hospital between January 2015 and July 2021 were registered, as shown in Fig. 1. Aortic disease was defined as a disorder of the aorta such as aortic aneurysm, aortic dissection, and aortic valve disease. One patient had received TXA from another hospital before transfer to our institution. Fourteen patients were administered TXA without bleeding symptoms. Among those 14 patients, six had no bleeding and were administered TXA monotherapy because of a gradual worsening in coagulation markers such as elevation of D-dimer. Eight patients received TXA for endoleak after endovascular aneurysm repair (EVAR). We evaluated improvements in bleeding symptoms with TXA in 14 patients. DIC score, bleeding symptoms, thrombotic complications, laboratory values, treatments, and outcomes were assessed. The change from baseline was analyzed with Wilcoxon matched pairs signed-rank test, excluding missing values. Kaplan-Meier curves were used to analyze overall survival. This study was performed in accordance with the Declaration of Helsinki and was approved by our ethics committee (approval no. 2022–0060).

### Criteria for diagnosis of DIC

The diagnostic criteria for DIC established by the Japanese Ministry of Health and Welfare (JMHW) were used



**Fig. 1** Patient selection. TXA: tranexamic acid

to diagnose DIC [12]. The JMHW diagnostic criteria for DIC are shown in Supplemental Table 1 (see Additional file 1). Underlying disease, clinical symptoms, platelet count, fibrin degradation product (FDP), fibrinogen, and prothrombin time (PT) ratio were evaluated. JMHW DIC scores >6 were considered diagnostic of DIC. A patient with a score of 6 was diagnosed as having DIC if at least two of the “Supplemental diagnostic laboratory results and findings” were met. Three points were deducted for complications of liver failure. Bleeding symptoms were defined in accordance with International Society on Thrombosis and Haemostasis bleeding criteria [13, 14]. Resolution of bleeding symptoms was assessed within 30 days after TXA administration.

Supplementary Table 1 DIC diagnostic criteria. DIC, disseminated intravascular coagulation; N.A. not applicable; PT, prothrombin time; FDP, fibrin and fibrinogen degradation products; TAT, thrombin anti-thrombin complex. Values of D-dimer can be converted to values of FDP

## Results

### Patient characteristics

The background characteristics of patients are shown in Table 1. Median age was 78.5 years (range, 66–89 years), and 11 patients were male. Prior to TXA administration, 9 patients had undergone EVAR, 7 had undergone open aortic aneurysm repair, and 1 had undergone transcatheter aortic valve implantation. Only one patient had no previous treatment for primary aortic disease. Median JMHW diagnostic criteria score for DIC was 8.0 (range, 4–11). Except for the 1 patient with liver failure, the 13 remaining patients (92.8%) met the diagnostic criteria for DIC. Bleeding symptoms were bloody sputum in 2 cases, subcutaneous hemorrhage in 2 cases, and difficulty achieving hemostasis after bleeding procedures in 10 cases. The procedures that caused difficulty in hemostasis were hemodialysis in 5 cases, cardiac catheterization in 1 case, central venous catheter insertion in 1 case, surgery in 2 cases, blood testing in 1 case, thoracic drainage in 1 case, and tooth extraction in 1 case. Two cases received more than 2 units of red cell transfusion, meeting the criteria for major bleeding. Bleeding events in other cases were clinically relevant non-major bleeding.

Twelve patients had chronic kidney disease (CKD) due to nephrosclerosis in 4 cases, cholesterol embolization in 1, impaired blood flow due to thrombus in 1, bilateral renal artery embolization by EVAR for endoleak in 1, right nephrectomy in 1, and unknown cause in 4. One patient had chronic liver injury caused by congested liver due to chronic heart failure and chronic renal failure.

Median platelet count was  $64 \times 10^9/L$  (range,  $25\text{--}97 \times 10^9/L$ ). Median fibrinogen was 1.4 g/L (range,

0.56–2.94 g/L). Most cases displayed a near-normal PT ratio.

### Dosing and other treatments

Dosing of TXA and descriptions of transfusion, antiplatelet, and anticoagulation treatments are shown in Table 2 and Supplemental Table 2 (see Additional file 2). Thirteen of the 14 cases were evaluable. Median initial TXA dose was 4.5 mg/kg/day (range, 0.8–24.0 mg/kg/day). One patient with an initial dose of 1000 mg was reduced to 50 mg/day on day 3. In that case, hemodialysis had been introduced before initial TXA treatment. All patients continued low-dose TXA after hemostasis, in expectation of maintaining good control of consumptive coagulation. Median duration of treatment was 597 days (range, 6–2282 days). Six patients required platelet concentrate (PC) or plasma derivative transfusions within 30 days post-TXA. Two patients received transfusions of both fresh frozen plasma (FFP) and PC. Only 4 cases received one transfusion and no patients received regular transfusions. Six patients received antiplatelet or anticoagulant treatments before and after TXA. Two patients received short-term thrombomodulin before or after TXA for pre-operative DIC treatment. No other cases met indications for antiplatelet or anticoagulant therapy for DIC treatment.

### Bleeding outcomes

Bleeding outcomes are shown in Table 3. The median observation period was 448 days (0–2282 days; mean, 744 days), with resolution of bleeding symptoms confirmed by 30 days in 10 cases. In the remaining 4 cases without resolution of bleeding symptoms within 30 days, 1 case experienced worsening bleeding, 1 case showed improvement of bleeding on day 33, and data were lacking in 2 cases. Of the 10 cases showing resolution of bleeding symptoms by 30 days, median time to improvement was 5.0 days (range, 2–22 days; mean, 6.2 days). Among the 11 cases that achieved a decrease in bleeding symptoms, TXA was continued for a median of 748 days (range, 21–2277 days; mean, 906 days) for bleeding prophylaxis. During the 30 days in which bleeding symptoms were observed, three cases received transfusion of 2 units of red blood cells (RBC), and one case with complications of sepsis on day 17 received transfusion of 8 units of RBCs. Although bleeding symptoms were under control, this patient died of sepsis on day 27.

Median overall survival was 2119 days (mean, 1459 days). Five patients died, one each from discontinuation of hemodialysis, aspiration pneumonia, brainstem hemorrhage, chronic DIC, and unknown cause. In the patient who died of brainstem hemorrhage, TXA was administered for 30 months then discontinued due to gradual decline of renal function, and no association with TXA could be confirmed.

**Table 1** Baseline characteristics

|  | <i>n</i> = 14 |                      |
|--|---------------|----------------------|
| Age, years, median (range, mean)                                 | 78.5          | (66–89, 78.2)        |
| Sex, male, <i>n</i> (%)  | 11            | (78.5)               |
| CKD (eGFR < 60), <i>n</i> (%)                                    | 12            | (85.7)               |
| Hemodialysis <sup>a</sup> , <i>n</i> (%)                         | 6             | (42.8)               |
| Liver failure <sup>b</sup> , <i>n</i>                            | 1             |                      |
| JMHW DIC score, median (range, mean)                             | 8.0           | (4–11, 7.7)          |
| Platelet count ( $\times 10^9/L$ ), median (range, normal range) | 64            | (25–97, 158–348)     |
| FDP ( $\mu g/mL$ ), median (range, normal range)                 | 100           | (19–270, < 10)       |
| D-dimer ( $\mu g/mL$ ), median (range, normal range)             | 44.3          | (13.4–93.7, < 1.0)   |
| FDP/D-dimer, median (range)                                      | 2.3           | (1.2–4.2)            |
| Fibrinogen (g/L), median (range, normal range)                   | 1.4           | (0.56–2.94, 2.0–4.0) |
| PT ratio, median (range)   | 1.15          | (1.02–1.55)          |
| ATIII (%), median (range, normal range)                          | 78            | (56–101, 80–120)     |
| TAT (ng/mL), median (range, normal range)                        | 45.9          | (10.9–97.5, 0–4.0)   |
| PIC ( $\mu g/mL$ ), median (range, normal range)                 | 5.0           | (2.1–10.9, 0–0.8)    |
| Bleeding event (overlap included), <i>n</i>                      | 14            |                      |
| Difficult hemostasis   | 10            |                      |
| after hemodialysis   | 5             |                      |
| after cardiac catheterization                                    | 1             |                      |
| after central venous catheter insertion                          | 1             |                      |
| during or after surgery  | 2             |                      |
| after blood test   | 1             |                      |
| after thoracic drainage  | 1             |                      |
| after tooth extraction   | 1             |                      |
| Subcutaneous hemorrhage  | 2             |                      |
| Bloody sputum  | 2             |                      |
| Aortic treatment prior to TXA, <i>n</i>                          | 13            |                      |
| Number of aortic treatments prior to TXA, median (range)         | 2.0           | (0–4)                |
| EVAR, <i>n</i>   | 9             |                      |
| Days from the most recent treatment, median (range)              | 1192          | (4–5410)             |
| Open aortic aneurysm repair, <i>n</i>                            | 7             |                      |
| Days from the most recent treatment, median (range)              | 678           | (3–3088)             |
| Transcatheter aortic valve implantation, <i>n</i>                | 1             |                      |
| Days from the most recent treatment                              | 88            |                      |
| Transfusion 30 days prior to TXA, <i>n</i>                       | 4             |                      |
| RBC  | 4             |                      |
| FFP  | 3             |                      |
| Fibrinogen   | 2             |                      |
| PC   | 2             |                      |

<sup>a</sup> Includes cases in which planned hemodialysis was introduced the day after the start of TXA administration

<sup>b</sup> Liver failure was defined as chronic liver disease with Child-Pugh B or C

CKD Chronic kidney disease, eGFR Estimated glomerular filtration rate, JMHW Japanese Ministry of Health and Welfare, DIC Disseminated intravascular coagulation, FDP Fibrin and fibrinogen degradation products, PT Prothrombin time, CKD Chronic kidney disease, AT Antithrombin, TAT Thrombin anti-thrombin complex, PIC Plasmin- $\alpha$ 2 plasmin inhibitor complex, TXA Tranexamic acid, EVAR Endovascular aneurysm repair, RBC Red blood cell, FFP Fresh frozen plasma, PC Platelet concentrate

### Laboratory data

Comparing median values before and after initiation of TXA, significant improvements were seen

in platelet count, FDP, D-dimer, and thrombin-antithrombin complex (TAT) ( $p < 0.05$ ). No significant improvements were seen for PT ratio, activated partial

**Table 2** Description of TXA and transfusion treatment

|  | <i>n</i> = 14 |                 |
|--|---------------|-----------------|
| TXA duration, days, median (range, mean)                       | 597           | (6–2282, 776)   |
| Initial TXA dose, mg/day, median (range, mean)                 | 250           | (50–1000, 314)  |
| Final TXA dose, mg/kg/day, median (range, mean)                | 5.5           | (2.3–15.0, 5.8) |
| Final TXA dose, mg/day, median (range, mean)                   | 250           | (150–500, 282)  |
| PC or plasma derivative transfusion within 30 days post-TXA, n | 6             |                 |
| FFP  | 4             |                 |
| Fibrinogen   | 1             |                 |
| PC   | 3             |                 |

TXA Tranexamic acid, PC Platelet concentrate, FFP Fresh frozen plasma

**Table 3** Bleeding outcomes and causes of death

|  | <i>n</i> = 14 |        |
|--|---------------|--------|
| Decrease of bleeding symptoms, n (%)                     | 11            | (78.5) |
| Increase of bleeding symptoms, n                         | 1             |        |
| No data, n   | 2             |        |
| Time to improvement within 30 days, days, median (range) | 5.0           | (2–22) |
| RBC transfusion, n                                       | 4             |        |
| Seizures, n  | 0             |        |
| Thrombosis, n  | 0             |        |
| Death, n (%)   | 5             | (35.7) |
| Brain hemorrhage   | 1             |        |
| Infection  | 1             |        |
| Hemodialysis termination                                 | 1             |        |
| Chronic DIC  | 1             |        |
| Unknown  | 1             |        |

RBC Red blood cell, DIC Disseminated intravascular coagulation

thromboplastin time (APTT), fibrinogen, antithrombin, plasmin-alpha2 plasmin inhibitor ( $\alpha$ 2PI) complex (PIC), or JMWH DIC score (Fig. 2).

### Adverse events

None of the patients showed thrombosis or seizures as an adverse event (Table 3). Figure 2 shows changes in serum creatinine before and after TXA among non-dialysis patients. No significant increase in creatinine was evident after TXA administration ( $p = 0.7188$ ).

### Discussion


Consumptive coagulopathy associated with aortic disease progresses to the state of enhanced fibrinolytic-type DIC (EFDIC). Yamada et al. reported that EFDIC is characterized by decreased platelet count, fibrinogen and  $\alpha$ 2PI

and increased TAT, PIC, FDP and D-dimer, while PT and APTT are less prolonged [15]. Elevated PIC is also characteristic, particularly in EFDIC, with some previous reports describing PIC > 10 g/mL as characteristic of EFDIC. The data from this study showed a trend generally consistent with these characteristics of EFDIC, but median PIC was 5.0 g/mL (range, 2.1–10.9  $\mu$ g/mL), which is low for EFDIC. Previous case reports of CDAAD showed PICs ranging from 0.8 to 10.6  $\mu$ g/mL, generally similar to the present study [6–11, 16, 17]. The degree of PIC elevation in CDAAD may thus be characterized as “not elevated”.

The dose of TXA administered in this study was quite low, around 30% of the dose normally used, and resulted in a significant reduction in FDP, one measure of increased fibrinolysis, but little reduction in PIC. A possible reason explaining why such low doses were effective in improving bleeding symptoms is that fibrinolysis is not as severe in CDAAD and is not the only major cause of bleeding symptoms.

The abnormal coagulation seen in the present study was not only fibrinolytic, but also coagulopathic, considering that TAT was also elevated. Therefore, a complex coagulation abnormality was considered to be caused by an imbalance between coagulation and fibrinolysis, rather than a state of increased fibrinolysis alone, suggesting that the inhibition of fibrinolysis by TXA does not contribute to the improvement of bleeding symptoms alone. Another possibility is that TXA-induced fibrinolysis inhibition may lead to an improvement in overall coagulation balance, in turn leading to improved bleeding symptoms.

Although oral TXA produced improvements in bleeding tendency, no significant difference in JMWH DIC score was identified. This is because platelet count, fibrinogen, and FDP must improve significantly to be reflected in an improved score. Another reason may be that this scoring system reflects improvements not only in bleeding symptoms, but also in items not directly related to coagulability, such as underlying disease and



**Fig. 2** Changes in laboratory data before and after TXA initiation. Median laboratory data from day 2 to day 30 was analyzed as data after TXA initiation. DIC score was assessed using JMHW diagnostic criteria. TXA: tranexamic acid; DIC: disseminated intravascular coagulation; JMHW: Japanese Ministry of Health and Welfare; PT: prothrombin time; APTT: activated partial thromboplastin time; FDP: fibrin degradation product; PIC: plasmin- $\alpha$ 2 plasmin inhibitor complex; TAT: thrombin-antithrombin complex

organ damage. In any case, the effect of low-dose TXA appeared to be an improvement in bleeding tendency, while DIC may not be improved.

However, although not evaluated in the present study, Aoki et al. reported that concomitant use of long-term TXA (1500mg/day for 6 months) in endovascular repair procedures resulted in a size reduction of aneurysms without any severe adverse events [18]. As such, TXA may not only directly improve blood coagulability, but also have an effect on the underlying aortic lesion, which would make this a very attractive treatment for CDAAD.

With regard to safety, deaths due to thrombotic complications have been reported with the use of TXA as a single agent in DIC with underlying diseases other than aortic disease [15, 19, 20]. However, no reports to date have described thrombosis with TXA monotherapy for CDAAD, and no thrombotic events occurred in

the present study. No other side effects could be clearly attributed to TXA.

Retrospectively, all cases in the present study continued TXA for bleeding prophylaxis and CDAAD control after achieving hemostasis. This is because relapse of severe bleeding symptoms after TXA discontinuation have been reported, and prolonged concomitant use of anticoagulants and TXA has been reported as useful for controlling bleeding symptoms and DIC [10, 21]. However, heparin is mainly used as the anticoagulant, and injections cannot be avoided. Several reports have described direct oral anticoagulants as an effective additional oral pharmacotherapy for CDAAD [22, 23]. However, direct oral anticoagulants cannot be used in patients with reduced renal function and are therefore often unsuitable in patients with CDAAD, many of whom have CKD. TXA also requires dose adjustment in

CKD patients, with Ma et al. recommending oral doses of 7.5–15 mg/kg/day for non-dialysis CKD patients [24]. The dose of approximately 5 mg/kg/day adopted in the present study can be administered to non-dialysis CKD patients without problems.

Finally, several limitations need to be considered in this study. First, this was a retrospective study of a small number of patients and TXA cannot be concluded to be effective based on improved outcomes. Two patients underwent EVAR during the observation period, and hemostatic effects of factors other than TXA cannot be ruled out. Future studies should assess the clinical efficacy of TXA in well-conditioned, prospective trials, while detailed assessment of blood coagulation performance is needed to determine exactly which coagulation findings are altered and which bleeding trends are improved by TXA.

## Conclusions

For bleeding symptoms due to consumptive coagulopathy associated with aortic disease, oral treatment with low-dose TXA resulted in improvement of bleeding symptoms without apparent side effects. Further studies are needed to validate this treatment.

## Abbreviations

|              |   |
|--------------|---|
| DIC          | Disseminated intravascular coagulation        |
| TXA          | Tranexamic acid                               |
| CDAAD        | Chronic DIC associated with aortic disease    |
| EVAR         | Endovascular aneurysm repair                  |
| JMHW         | Japanese Ministry of Health and Welfare       |
| FDP          | Fibrin degradation product                    |
| PT           | Prothrombin time                              |
| CKD          | Chronic kidney disease                        |
| PC           | Platelet concentrate                          |
| FFP          | Fresh frozen plasma                           |
| RBC          | Red blood cell                                |
| TAT          | Thrombin-antithrombin complex                 |
| APTT         | Activated partial thromboplastin time         |
| $\alpha$ 2PI | $\alpha$ 2 plasmin inhibitor                  |
| PIC          | Plasmin- $\alpha$ 2 plasmin inhibitor complex |
| EFDIC        | Enhanced fibrinolytic-type DIC                |

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12959-022-00429-4>.

**Additional file 1: Supplemental Table 1.** DIC diagnostic criteria established by JMHW. Values of D-dimer can be converted to values of FDP. DIC: disseminated intravascular coagulation; JMHW: Japanese Ministry of Health and Welfare; PT: prothrombin time; FDP: fibrin and fibrinogen degradation products; TAT, thrombin-anti-thrombin complex; PIC: plasmin- $\alpha$ 2 plasmin inhibitor complex.

**Additional file 2: Supplemental Table 2.** Descriptions of patients using antiplatelet or anticoagulant treatments before and after TXA. † Days before and after TXA (starting from the date of TXA initiation). TXA: tranexamic acid; NA: not applicable; DIC: disseminated intravascular coagulation.

## Acknowledgements

Not applicable.

## Authors' contributions

TM, NS, YK, SO, TK, AS, ST, TK, and NS made substantial contributions to the conception of the manuscript, and revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

## Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

## Availability of data and materials

The datasets generated and analyzed during the present study are available from the corresponding author on reasonable request.

## Declarations

### Ethics approval and consent to participate

This study was approved by the *Ethics Committee of Nagoya University Graduate School of Medicine*.

### Consent for publication

This paper does not report on primary research. All data analyzed were collected as part of routine diagnosis and treatment.

### Competing interests

KH has received research grants from Daiichi Sankyo Company, Limited.

### Author details

<sup>1</sup>Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan. <sup>2</sup>Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan. <sup>3</sup>Department of Clinical Laboratory, Nagoya University Hospital, Nagoya, Japan. <sup>4</sup>Department of Hematology, National Center of Geriatrics and Gerontology, Obu, Japan. <sup>5</sup>Department of Medical Technique, Nagoya University Hospital, Nagoya, Japan. <sup>6</sup>Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan. <sup>7</sup>Present address: Department of Medical Laboratory Science, Hokkaido University Graduate School of Health Science, Sapporo, Japan. <sup>8</sup>Aichi Health Promotion Foundation, Nagoya, Japan.

Received: 29 July 2022 Accepted: 4 November 2022

Published online: 25 January 2023

## References

- Group JJW. Guidelines for diagnosis and treatment of aortic aneurysm and aortic dissection (JCS 2011). *Circ J*. 2013;77(3):789–828.
- Levi M, Scully M. How I treat disseminated intravascular coagulation. *Blood*. 2018;131(8):845–54.
- Zhang Y, Li C, Shen M, Liu B, Zeng X, Shen T. Aortic aneurysm and chronic disseminated intravascular coagulation: a retrospective study of 235 patients. *Front Med*. 2017;11(1):62–7.
- Cai J, Ribkoff J, Olson S, Raghunathan V, Al-Samkari H, Deloughery TG, et al. The many roles of tranexamic acid: an overview of the clinical indications for TXA in medical and surgical patients. *Eur J Haematol*. 2020;104(2):79–87.
- Franchini M, Mannucci PM. The never ending success story of tranexamic acid in acquired bleeding. *Haematologica*. 2020;105(5):1201–5.
- Gatate Y, Masaki N, Sato A, Yasuda R, Namba T, Yada H, et al. Tranexamic acid controlled chronic disseminated intravascular coagulation associated with aortic dissection and patent false lumen for three years. *Intern Med*. 2017;56(8):925–9.
- Werbin A, Fong A, Shahin G, Henderson A, Surry L. Tranexamic acid use in a patient with a life-threatening bleed exacerbated by coagulopathy due to an aortic aneurysm with an Endoleak: a case report. *Cureus*. 2019;11(8):e5486.
- Kikusaki S, Akaiwa K, Nakamura K, Oda T. Tranexamic acid is effective for DIC complicated with aortic dissection or aortic aneurysm. *Japan J Cardiovasc Surg*. 2020;49(5):305–9.

9. Suzuki R, Shiina E, Gunji M, Hasumi S, Kurosawa H, Sato C, et al. A dialysis patient who was successfully treated with recombinant thrombomodulin and tranexamic acid for various bleeding symptoms due to chronic DIC associated with an aortic aneurysm and secondary factor XIII deficiency. *Nihon Toseki Igakkai Zasshi*. 2020;53(8):439–46.
10. Yip PL, Lau SMJ, Lee TYJ. Severe bleeding tendency due to excessive fibrinolysis in two patients with aortic disease: role of Tranexamic acid in non-surgical candidate. *J Med Cases*. 2020;11(10):303–5.
11. Eguchi E. Oral tranexamic acid combined with low molecular weight heparin only during dialysis sessions successfully controlled chronic disseminated intravascular coagulation associated with aortic aneurysm and aortic dissection in a dialysis patient: a case report. *Ren Replace Ther*. 2019;5(1):34.
12. Kobayashi N, Maekawa T, Takada M, Tanaka H, Gonmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the research committee on DIC in Japan. *Bibl Haematol*. 1983;49:265–75.
13. Bauersachs RBS, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. *N Engl J Med*. 2010;363(26):2499–510.
14. Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. *J Thromb Haemost*. 2015;13(11):2119–26.
15. Yamada S, Asakura H. Management of disseminated intravascular coagulation associated with aortic aneurysm and vascular malformations. *Int J Hematol*. 2021;113(1):15–23.
16. Kurihara I, Yamaguchi Y, Soma J, Sato H, Ito S, Saito T. Two aged patients with chronic renal failure and chronic disseminated intravascular coagulation secondary to aortic aneurysms: effect of continuous subcutaneous heparin infusion therapy. *Nihon Jinzo Gakkai Shi*. 2000;42(7):603–7.
17. Togami K, Nagai Y, Arima H, Shimoji S, Kimura T, Inoue D, et al. Successful treatment of chronic disseminated intravascular coagulation syndrome with continuous subcutaneous infusion of heparin using a mobile infusion pump: report of 2 cases. *Rinsho Ketsueki*. 2009;50(12):1700–5.
18. Aoki A, Suezawa T, Yamamoto S, Sangawa K, Irie H, Mayazaki N, et al. Effect of antifibrinolytic therapy with tranexamic acid on abdominal aortic aneurysm shrinkage after endovascular repair. *J Vasc Surg*. 2014;59(5):1203–8.
19. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. *Br J Haematol*. 2009;145(1):24–33.
20. Naeye RL. Thrombotic state after a hemorrhagic diathesis, a possible complication of therapy with epsilon-Aminocaproic acid. *Blood*. 1962;19(6):694–701.
21. Yamada S, Asakura H. Therapeutic strategies for disseminated intravascular coagulation associated with aortic aneurysm. *Int J Mol Sci*. 2022;23(3):1296.
22. Kawano H, Hata T, Uda A, Maemura K. Use of rivaroxaban for the effective Management of Disseminated Intravascular Coagulation Associated with abdominal aortic aneurysm. *Intern Med*. 2015;54(20):2625–8.
23. Janjetovic S, Holstein K, Dicke C, Bokemeyer C, Langer F. Apixaban for the treatment of chronic disseminated intravascular coagulation: a report of two cases. *Hamostaseologie*. 2019;39(3):294–7.
24. Ma TK-W, Chow KM, Kwan BC-H, Leung CB, Szeto CC, Li PK-T. Manifestation of tranexamic acid toxicity in chronic kidney disease and kidney transplant patients: a report of four cases and review of literature. *Nephrology*. 2017;22(4):316–21.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)





Supplemental table 1

|   |                        | Score |
|---|------------------------|-------|
| Underlying disease                                      | Absent                 | 0     |
|   | Present                | 1     |
| Bleeding symptoms                                       | Absent                 | 0     |
|   | Present                | 1     |
| Organ dysfunction                                       | Absent                 | 0     |
|   | Present                | 1     |
| Platelet count ( $\times 10^9/L$ )                      | >120                   | 0     |
|   | > 80 and $\leq 120$    | 1     |
|   | > 50 and $\leq 80$     | 2     |
|   | $\leq 50$              | 3     |
| PT ratio  | < 1.25                 | 0     |
|   | $\geq 1.25$ and < 1.67 | 1     |
|   | $\geq 1.67$            | 2     |
| Fibrinogen (g/L)  | >1.5                   | 0     |
|   | > 1.0 and $\leq 1.5$   | 1     |
|   | $\leq 1.0$             | 2     |
| FDP ( $\mu g/mL$ )                                      | < 10                   | 0     |
|   | $\geq 10$ and < 20     | 1     |
|   | $\geq 20$ and < 40     | 2     |
|   | $\geq 40$              | 3     |
| Liver failure, hepatic cirrhosis, or severe hepatitis   | Absent                 | 0     |
|   | Present                | -3    |
| Supplemental diagnostic laboratory results and findings |                        |       |
| 1) Positive soluble fibrin monomer                      |                        |       |
| 2) Elevated D-dimer                                     |                        |       |

- 
- 3) Elevated TAT
  - 4) Elevated PIC level
  - 5) Emergence of an increasing trend in scores as the disease progresses.  
In particular, a sharp decrease in platelet count or fibrinogen or a sharp increase in FDP within a few days.
  - 6) Improvement with anticoagulation therapy.
-

Supplemental table 2

| <b>Case</b> | <b>Indication for treatment</b> | <b>Treatment</b>  | <b>Initiation<sup>†</sup></b> | <b>Bleeding<sup>†</sup></b> | <b>Hemostasis<sup>†</sup></b> | <b>Discontinuation<sup>†</sup></b> | <b>Reason of Discontinuation</b> |
|-------------|---------------------------------|-------------------|-------------------------------|-----------------------------|-------------------------------|------------------------------------|----------------------------------|
| <b>1</b>    | Atrial fibrillation             | Heparin, warfarin | -29                           | 0                           | 4                             | 14                                 | Cessation of arrhythmia          |
| <b>2</b>    | Atrial fibrillation             | Rivaroxaban       | -378                          | -4                          | 5                             | -4                                 | Operation                        |
| <b>3</b>    | Angina                          | Aspirin           | -670                          | -2                          | 2                             | Continued                          | NA                               |
| <b>4</b>    | Cerebral infarction             | Cilostazol        | -66                           | -9                          | 5                             | Continued                          | NA                               |
| <b>5</b>    | Preoperative DIC treatment      | Thrombomodulin    | -7                            | -1                          | 3                             | -5                                 | Operation                        |
| <b>6</b>    | Preoperative DIC treatment      | Thrombomodulin    | 26                            | -2                          | 2                             | 34                                 | Operation                        |